Filipe Pereira

Lund University in Sweden is offering a postdoctoral position in computational immunology and bioinformatics, focusing on cancer immunotherapy, multiomics data analysis, T cell-mediated antitumor immunity, and neoantigen identification. The position is part of a collaborative project funded by the Knut and Alice Wallenberg Foundation, involving the Human Systems Immunology Lab (led by Camila Rosat Consiglio) and the Cell Reprogramming in Hematopoiesis and Immunity Lab (led by Filipe Pereira). The research aims to investigate how reprogrammed cancer cells induce anti-tumor immune responses using advanced multiomics and computational approaches. The ideal candidate will have a PhD in bioinformatics, computational biology, or a related field, with strong experience in next generation sequencing data analysis, programming, and scripting. Candidates should be enthusiastic, motivated, and able to work in a multidisciplinary environment. Excellent English communication skills are required. The position offers access to world-class research facilities, including flow cytometry, cell sorting, and genomics platforms, and provides a highly interactive environment with regular seminars and retreats. The preferred start date is between June and October 2026. Applications must be submitted via the provided Google Forms link by February 20th, 2026. For more information, candidates are encouraged to visit the lab websites and review the project details.

PhD position in Computational Immune Reprogramming at Lund University This doctoral opportunity is in the Pereira Lab at Lund University , within the Department of Laboratory Medicine and the Faculty of Medicine . The project is part of the SciLifeLab Data-Driven Life Science (DDLS) program and the DDLS Research School . The research focuses on computational biology , bioinformatics , single-cell RNA-seq , multi-omics , machine learning , and mathematical/statistical modelling to build a virtual screening platform for immune cell reprogramming . The student will analyze REPROcode data, identify induced immune cell states, map transcription factor networks, and predict new transcription factor combinations that drive immune identity. The broader biomedical context includes cancer immunotherapy , immunology , and cell fate reprogramming . The lab studies how hematopoietic and immune cell identities are specified and modified, with translational interests in improving anti-tumor immune responses. The project is highly interdisciplinary and suited to candidates who enjoy combining computational and biological questions in a collaborative research environment. Eligibility highlights: a Master’s degree or equivalent in a relevant field; experience with next-generation sequencing data, preferably single-cell and/or other omics data; programming in Python and/or R; familiarity with tools such as Seurat or Scanpy; strong English communication skills; and the ability to work independently and in teams. Additional experience in cancer immunology, immunotherapy, hematopoiesis, multi-omics integration, statistical modelling, machine learning, or data visualization is advantageous. Funding and terms: the position is funded by DDLS, is a temporary doctoral appointment for four years, and includes a monthly salary. The start date is intended to be 1 October 2026 or as agreed. Application window: published 13 April 2026; last application date 17 May 2026. How to apply: submit the application through Lund University’s recruitment system. Prepare a one-page cover letter, CV with publications, a one-page description of previous computational work, degree documents, two letters of recommendation, and any other relevant supporting materials.

Lund University in Sweden is recruiting three tenure-track Assistant Professors as part of its Programme for Global Excellence to strengthen research in immunotherapy and immuno-oncology . The openings span three closely related areas: Immunotechnology with a focus on cancer immunotherapy , Immuno-Oncology and Immune Cell Engineering , and Experimental Cancer Immunotherapy . The posts are based at Lund University units including the Department of Immunotechnology, the Division of Immuno-Oncology, and the Division of Translational Cancer Research. These are tenure-track faculty positions with a clear path to promotion and an attractive start-up package. The post is aimed at outstanding researchers who can build an internationally competitive programme at the interface of immune engineering , mechanistic discovery , and clinical translation . Eligibility highlights vary slightly by position, but candidates are expected to hold a PhD ; one position accepts PhD and/or MD . A strong background in the relevant research area is required, especially in cancer immunotherapy, immuno-oncology, immunotechnology, or immune cell engineering. Deadlines shown in the post are 26 May 2026 for Immunotechnology, 30 June 2026 for Immuno-Oncology and Immune Cell Engineering, and 10 June 2026 for Experimental Cancer Immunotherapy. Application links are provided via Lund University’s Varbi portal. Contact persons listed in the post include Professor Sara Ek , Professor Filipe Pereira , and Professor Kristian Pietras .

Lund University is recruiting an Assistant Professor (Tenure Track) in Immuno-Oncology and Immune Cell Engineering as part of the Lund University Programme for Global Excellence . This opportunity is aimed at outstanding researchers who want to build an internationally competitive research programme at the interface of immuno-oncology , immune cell engineering , cancer immunology , mechanistic discovery, and clinical translation. The post is based in the Division of Immuno-Oncology at the Faculty of Medicine, Lund University . The position is a tenure-track appointment at assistant professor level and includes a clear path to promotion. The announcement also highlights a substantial start-up package / attractive start-up support for the successful candidate. Eligibility highlights: candidates must hold a PhD and/or MD and have a strong background in immuno-oncology and immunotherapy. The post is especially relevant for researchers with experience or interest in immune engineering, translational cancer research, and building an independent research group. Application deadline: 10 June 2026. How to apply: submit the application via the Lund University/Varbi application link. For questions, contact Professor Filipe Pereira at [email protected] .